Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week Flexible-Dose Open-Label Extension to a 40-Week Double-Blind Randomised Placebo-Controlled Core Study

摘要

IntroductionPreviously, in a 40-week, randomised, double-blind, placebo-controlled core study comprising three phases (9-week dose confirmation, 5-week open-labeldose optimisation and 6-month maintenance of effect) in adults with attention-deficit/hyperactivity disorder (ADHD), methylphenidate modified-release long-acting formulation (MPH-LA) at 40–80 mg/day controlled ADHD symptoms as well as decreased functional impairment with a good tolerability profile (). Here, we report the long-term efficacy and safety from a 26-week, open-label extension phase of the same study ().